PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor; reduces glycolytic flux and suppresses glucose uptake. Inhibits endothelial cell proliferation and causes G2
/M cell cycle arrest in vitro
. Attenuates vessel sprouting and tumor growth in vivo
. Amplifies the antiangiogenic effect of VEGFR blockade.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Clem et al.
Mol.Cancer Ther., 2008;7:110
Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis.
Schoors et al.
Cell Metab., 2014;19:37